CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肿瘤微环境在癌症进展与治疗策略中的作用
英文原题：Role of tumor microenvironment in cancer progression and therapeutic strategy.
查看英文原题
Role of tumor microenvironment in cancer progression and therapeutic strategy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
癌症如今被认为是一种肿瘤微环境（TME）相关疾病；过去，人们主要将其视为细胞和基因表达异常。过去20年中，对TME复杂性及其对包括免疫疗法在内的各种抗癌治疗反应的影响，研究取得了显著进展。癌症免疫疗法通过调节机体免疫系统识别并杀伤癌细胞，已在多种实体瘤和血液系统恶性肿瘤中取得良好疗效。近年来，针对程序性死亡受体1（PD-1）、程序性死亡配体1（PD-L1）和程序性死亡配体2（PD-L2）的阻断疗法、抗原特异性嵌合受体T细胞（CAR-T）构建及肿瘤疫苗，已成为热门免疫治疗策略。肿瘤发生、进展和转移均与TME密切相关。因此，本文综述TME中各类细胞和分子的特征、PD-1与TME的相互作用，以及具有前景的癌症免疫治疗方法。
展开英文摘要原文
Cancer is now considered a tumor microenvironment (TME) disease, although it was originally thought to be a cell and gene expression disorder. Over the past 20 years, significant advances have been made in understanding the complexity of the TME and its impact on responses to various anticancer therapies, including immunotherapies. Cancer immunotherapy can recognize and kill cancer cells by regulating the body's immune system.
It has achieved good therapeutic effects in various solid tumors and hematological malignancies. Recently, blocking of programmed death-1 (PD-1), programmed death-1 ligand-1 (PD-L1), and programmed death Ligand-2 (PD-L2), the construction of antigen chimeric T cells (CAR-T) and tumor vaccines have become popular immunotherapies Tumorigenesis, progression, and metastasis are closely related to TME.
Therefore, we review the characteristics of various cells and molecules in the TME, the interaction between PD-1 and TME, and promising cancer immunotherapy therapeutics.
论文信息
- 作者
- Wang Q、Shao X、Zhang Y、Zhu M、Wang FXC、Mu J、Li J、Yao H
- 单位
- Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cancer medicine2023 May
- 原文标识
- PubMed 36807772 · DOI 10.1002/cam4.5698
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →